1. Home
  2. STEM vs KPTI Comparison

STEM vs KPTI Comparison

Compare STEM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stem Inc.

STEM

Stem Inc.

HOLD

Current Price

$12.46

Market Cap

137.9M

Sector

Technology

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.75

Market Cap

148.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEM
KPTI
Founded
2009
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.9M
148.0M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
STEM
KPTI
Price
$12.46
$6.75
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$14.60
$22.17
AVG Volume (30 Days)
272.1K
433.7K
Earning Date
03-03-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$164,948,000.00
$142,530,000.00
Revenue This Year
$3.43
$3.55
Revenue Next Year
$12.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.81
$3.51
52 Week High
$32.23
$10.38

Technical Indicators

Market Signals
Indicator
STEM
KPTI
Relative Strength Index (RSI) 26.23 48.76
Support Level $17.26 $6.06
Resistance Level $16.23 $6.88
Average True Range (ATR) 1.56 0.53
MACD -0.63 -0.05
Stochastic Oscillator 2.11 60.75

Price Performance

Historical Comparison
STEM
KPTI

About STEM Stem Inc.

Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: